{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:56:20Z","timestamp":1790265380962,"version":"4.1.0"},"reference-count":159,"publisher":"Elsevier BV","issue":"4-5","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1016\/j.neuropharm.2010.02.010","type":"journal-article","created":{"date-parts":[[2010,2,15]],"date-time":"2010-02-15T04:27:29Z","timestamp":1266208049000},"page":"221-229","source":"Crossref","is-referenced-by-count":88,"title":["Neurochemical basis for symptomatic treatment of Alzheimer's disease"],"prefix":"10.1016","volume":"59","author":[{"given":"Paul T.","family":"Francis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda J.","family":"Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell K.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2010.02.010_bib1","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.nbd.2005.05.001","article-title":"Impaired metabotropic glutamate receptor\/phospholipase C signaling pathway in the cerebral cortex in Alzheimer's disease and dementia with Lewy bodies correlates with stage of Alzheimer's-disease-related changes","volume":"20","author":"Albasanz","year":"2005","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00004850-199100630-00002","article-title":"Agitation in the demented elderly: a role for benzodiazepines?","volume":"6","author":"Ancill","year":"1991","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib3","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/0278-5846(92)90106-O","article-title":"Neurotransmitter changes in early- and late-onset Alzheimer-type dementia","volume":"16","author":"Arai","year":"1992","journal-title":"Progress in Neuropsychopharmacology and Biological Psychiatry"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib4","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1111\/j.1471-4159.1988.tb02497.x","article-title":"Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease","volume":"50","author":"Araujo","year":"1988","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003154.pub3","article-title":"Memantine for dementia","author":"Areosa","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib6","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0006-8993(94)91732-9","article-title":"AMPA-selective glutamate receptor subtype immunoreactivity in the entorhinal cortex of non-demented elderly and patients with Alzheimer's disease","volume":"639","author":"Armstrong","year":"1994","journal-title":"Brain Research"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0301-0082(02)00079-5","article-title":"Alzheimer's disease and the basal forebrain cholinergic system: relations to \u03b2-amyloid peptides, cognition, and treatment strategies","volume":"68","author":"Auld","year":"2002","journal-title":"Progress in Neurobiology"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib8","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003476.pub2","article-title":"The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease","author":"Ballard","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib9","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1126\/science.7046051","article-title":"The cholinergic hypothesis of geriatric memory dysfunction","volume":"217","author":"Bartus","year":"1982","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib10","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/(SICI)1097-4547(19990115)55:2<218::AID-JNR9>3.0.CO;2-L","article-title":"Interindividual differences in the levels of the glutamate transporters GLAST and GLT, but no clear correlation with Alzheimer's disease","volume":"55","author":"Beckstrom","year":"1999","journal-title":"Journal of Neuroscience Research"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib11","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.mehy.2009.09.011","article-title":"\u03b17 neuronal nicotinic receptors: the missing link to understanding Alzheimer's etiopathology?","volume":"74","author":"Bencherif","year":"2010","journal-title":"Medical Hypotheses"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib12","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1471-4159.1983.tb11838.x","article-title":"Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer's disease","volume":"41","author":"Bowen","year":"1983","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib13","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0022-510X(82)90026-0","article-title":"Choline acetyltransferase activity and histopathology of frontal neocortex from biopsies of demented patients","volume":"57","author":"Bowen","year":"1982","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathologica (Berlin)"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0006-8993(95)00104-X","article-title":"The distribution of 5-HT1A and 5-HT2A receptor mRNA in human brain","volume":"676","author":"Burnet","year":"1995","journal-title":"Brain Research"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib16","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1046\/j.1471-4159.1996.66041592.x","article-title":"Presynaptic serotonergic markers in community-acquired cases of Alzheimer's disease: correlations with depression and neuroleptic medication","volume":"66","author":"Chen","year":"1996","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib17","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1046\/j.1365-2990.2000.00254.x","article-title":"Immunocytochemical study of the dorsal and median raphe nuclei in patients with Alzheimer's disease prospectively assessed for behavioural changes","volume":"26","author":"Chen","year":"2000","journal-title":"Neuropathology and Applied Neurobiology"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib18","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1523\/JNEUROSCI.12-11-04427.1992","article-title":"Open-channel block of N-methyl-d-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity","volume":"12","author":"Chen","year":"1992","journal-title":"Journal of Neuroscience"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib19","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1532-5415.1998.tb01081.x","article-title":"Alprazolam as an alternative to low-dose haloperidol in older, cognitively impaired nursing facility patients","volume":"46","author":"Christensen","year":"1998","journal-title":"Journal of the American Geriatric Society"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib20","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1586\/14737175.5.5.671","article-title":"Cholinergic and glutamatergic drugs in Alzheimer's disease therapy","volume":"5","author":"Clarke","year":"2005","journal-title":"Expert Reviews in Neurotherapeutics"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib21","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/0006-8993(88)90212-0","article-title":"Decreased densities of dopamine D1 receptors in the putamen and hippocampus in senile dementia of the Alzheimer type","volume":"475","author":"Cortes","year":"1988","journal-title":"Brain Research"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib22","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/0165-6147(96)10015-8","article-title":"Benzodiazepines on trial: a research strategy for their rehabilitation","volume":"17","author":"Costa","year":"1996","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib23","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/00007611-197506000-00015","article-title":"Alleviating agitation, apprehension, and related symptoms in geriatric patients: a double-blind comparison of a phenothiazine and a benzodiazepine","volume":"68","author":"Covington","year":"1975","journal-title":"Southern Medical Journal"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib24","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1471-4159.1989.tb10908.x","article-title":"Characterisation, density, and distribution of kainate receptors in normal and Alzheimer's diseased human brain","volume":"52","author":"Cowburn","year":"1989","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib25","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1111\/j.1471-4159.1984.tb06081.x","article-title":"Serotonin receptor changes in dementia of the Alzheimer type","volume":"43","author":"Cross","year":"1984","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0304-3940(84)90341-0","article-title":"Striatal dopamine receptors in Alzheimer-type dementia","volume":"52","author":"Cross","year":"1984","journal-title":"Neuroscience Letters"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib27","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1176\/ajp.157.1.4","article-title":"Cholinesterase inhibitors: a new class of psychotropic compounds","volume":"157","author":"Cummings","year":"2000","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib28","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/00019442-200005000-00008","article-title":"The relationship between donepezil and behavioral disturbances in patients with Alzheimer's disease","volume":"8","author":"Cummings","year":"2000","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib29","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1212\/WNL.47.4.876","article-title":"Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited","volume":"47","author":"Cummings","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib30","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/00005072-198407000-00001","article-title":"Nucleus raphe dorsalis in dementia of the Alzheimer type: neurofibrillary changes and neuronal packing density","volume":"43","author":"Curcio","year":"1984","journal-title":"Journal of Neuropathology and Experimental Neurology"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib31","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/ana.410220207","article-title":"Aminergic systems in Alzheimer's disease and Parkinson's disease","volume":"22","author":"D'Amato","year":"1987","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib32","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s007260070045","article-title":"NMDA channel blockers: memantine and amino-aklylcyclohexanes \u2013 in vivo characterization","volume":"19","author":"Danysz","year":"2000","journal-title":"Amino Acids"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib33","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0006-8993(79)90336-6","article-title":"Neurotransmitter-related enzymes in senile dementia of the Alzheimer type","volume":"171","author":"Davies","year":"1979","journal-title":"Brain Research"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib34","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0301-0082(98)00024-0","article-title":"First one in, last one out: the role of gabaergic transmission in generation and degeneration","volume":"55","author":"Davies","year":"1998","journal-title":"Progress in Neurobiology"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib35","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(76)91936-X","article-title":"Selective loss of central cholinergic neurons in Alzheimer's disease","volume":"2","author":"Davies","year":"1976","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib36","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1001\/jama.281.15.1401","article-title":"Cholinergic markers in elderly patients with early signs of Alzheimer disease","volume":"281","author":"Davis","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib37","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0893-133X(01)00265-2","article-title":"The 5-HT6 receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus","volume":"25","author":"Dawson","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib38","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1159\/000107099","article-title":"Reduction of phosphorylated tau during memantine treatment of Alzheimer's disease","volume":"24","author":"Degerman","year":"2007","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib39","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ana.10069","article-title":"Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment","volume":"51","author":"DeKosky","year":"2002","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib40","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1212\/WNL.52.6.1158","article-title":"The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease","volume":"52","author":"Delacourte","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib41","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/j.1476-5381.1995.tb15020.x","article-title":"NMDA-induced glutamate and aspartate release from rat cortical pyramidal neurones: evidence for modulation by a 5-HT1A antagonist","volume":"115","author":"Dijk","year":"1995","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib42","series-title":"Textbook of Geriatric Neuropsychiatry","first-page":"779","article-title":"Psychopharmacology","author":"Dubovsky","year":"2000"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib43","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/ana.410200510","article-title":"A postmortem study of amino acid neurotransmitters in Alzheimer's disease","volume":"20","author":"Ellison","year":"1986","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib44","doi-asserted-by":"crossref","first-page":"11141","DOI":"10.1073\/pnas.0403921101","article-title":"Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice","volume":"101","author":"Etcheberrigaray","year":"2004","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib45","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/ana.410290305","article-title":"Loss of high-affinity agonist binding to M1 muscarinic receptors in Alzheimer's disease: implications for the failure of cholinergic replacement therapies","volume":"29","author":"Flynn","year":"1991","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib46","series-title":"Alzheimer Disease","first-page":"25","article-title":"Noncognitive symptoms of Alzheimer disease","author":"Folstein","year":"1999"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib47","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1002\/gps.934","article-title":"Glutamatergic systems in Alzheimer's disease","volume":"18","author":"Francis","year":"2003","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib48","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1056\/NEJM198507043130102","article-title":"Neurochemical studies of early-onset Alzheimer's disease. Possible influence on treatment","volume":"313","author":"Francis","year":"1985","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib49","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/jnnp.66.2.137","article-title":"The cholinergic hypothesis of Alzheimer's disease: a review of progress","volume":"66","author":"Francis","year":"1999","journal-title":"Journal of Neurology Neurosurgery and Psychiatry"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib50","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0022-3565(25)11149-X","article-title":"5-Hydroxytryptamine1A but not 5-hydroxytryptamine2 receptors are enriched on neocortical pyramidal neurones destroyed by intrastriatal volkensin","volume":"261","author":"Francis","year":"1992","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib51","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1471-4159.1993.tb13381.x","article-title":"Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease: investigative and therapeutic perspectives","volume":"60","author":"Francis","year":"1993","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib52","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.neuropsychologia.2004.06.007","article-title":"Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease","volume":"43","author":"Garcia-Alloza","year":"2005","journal-title":"Neuropsychologia"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib53","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/sj.npp.1300330","article-title":"Differential involvement of 5-HT1B\/1D and 5-HT6 receptors in cognitive and non-cognitive symptoms in Alzheimer's disease","volume":"29","author":"Garcia-Alloza","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib54","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.neurobiolaging.2005.06.003","article-title":"Involvement of the GABAergic system in depressive symptoms of Alzheimer's disease","volume":"27","author":"Garcia-Alloza","year":"2006","journal-title":"Neurobiology of Aging"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib55","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/gps.1341","article-title":"Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies","volume":"20","author":"Gauthier","year":"2005","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib56","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/0006-3223(86)90222-2","article-title":"Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly","volume":"21","author":"Georgotas","year":"1986","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib57","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.nbd.2006.04.005","article-title":"Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies by immunoprecipitation","volume":"23","author":"Gotti","year":"2006","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib58","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0278-5846(88)90102-9","article-title":"Glutamate transmission and toxicity in Alzheimer's disease","volume":"12","author":"Greenamyre","year":"1988","journal-title":"Progress in Neuropsychopharmacology and Biological Psychiatry"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib59","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/j.1471-4159.1987.tb04127.x","article-title":"Dementia of the Alzheimer's type: changes in hippocampal l- [3H]glutamate binding","volume":"48","author":"Greenamyre","year":"1987","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib60","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1126\/science.2858129","article-title":"Alterations in l-glutamate binding in Alzheimer's and Huntington's diseases","volume":"227","author":"Greenamyre","year":"1985","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib61","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0014-827X(01)01102-8","article-title":"Muscarinic agonists and antagonists in the treatment of Alzheimer's disease","volume":"56","author":"Greenlee","year":"2001","journal-title":"Farmaco"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib62","first-page":"211","article-title":"Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis","volume":"3","author":"Hansen","year":"2008","journal-title":"Clinical Interventions in Aging"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib63","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/00019442-200008000-00007","article-title":"A retrospective chart review of gabapentin for the treatment of aggressive and agitated behavior in patients with dementias","volume":"8","author":"Hawkins","year":"2000","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib64","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/jnnp.71.6.777","article-title":"Psychosis and aggression in Alzheimer's disease: the effect of dopamine receptor gene variation","volume":"71","author":"Holmes","year":"2001","journal-title":"Journal of Neurology Neurosurgery and Psychiatry"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib65","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1471-4159.2001.00409.x","article-title":"Glutamate (NMDA) receptor NR1 subunit mRNA expression in Alzheimer's disease","volume":"78","author":"Hynd","year":"2001","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib66","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/j.1471-4159.2004.02548.x","article-title":"Differential expression of N-methyl-d-aspartate receptor NR2 isoforms in Alzheimer's disease","volume":"90","author":"Hynd","year":"2004","journal-title":"Journal of Neurochemistry"},{"issue":"Suppl. 3","key":"10.1016\/j.neuropharm.2010.02.010_bib67","first-page":"215","article-title":"Behavioral and psychological signs and symptoms of dementia: implications for research and treatment","volume":"8","author":"IPA","year":"1996","journal-title":"International Psychogeriatrics"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib68","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0306-4522(90)90246-Z","article-title":"Alzheimer's disease: changes in hippocampal N-methyl-d-aspartate, quisqualate, neurotensin, adenosine, benzodiazepine, serotonin and opioid receptors \u2013 an autoradiographic study","volume":"39","author":"Jansen","year":"1990","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib69","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s12031-002-0032-4","article-title":"Randomized, double-blind, placebo-controlled international clinical trial of the Ampakine CX516 in elderly participants with mild cognitive impairment: a progress report","volume":"19","author":"Johnson","year":"2002","journal-title":"Journal of Molecular Neuroscience"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib70","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0893-133X(98)00044-X","article-title":"Loss of dopamine D2 receptors in Alzheimer's disease with parkinsonism but not Parkinson's or Alzheimer's disease","volume":"19","author":"Joyce","year":"1998","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib71","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0197-4580(91)90051-K","article-title":"Adrenergic receptors in aging and Alzheimer's disease: decreased \u03b12-receptors demonstrated by [3H]p-aminoclonidine binding in prefrontal cortex","volume":"12","author":"Kalaria","year":"1991","journal-title":"Neurobiology of Aging"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib72","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1111\/j.1471-4159.1989.tb09242.x","article-title":"Adrenergic receptors in aging and Alzheimer's disease: increased \u03b22-receptors in prefrontal cortex and hippocampus","volume":"53","author":"Kalaria","year":"1989","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib73","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.neurobiolaging.2007.04.010","article-title":"Loss of VGLUT1 and VGLUT2 in the prefrontal cortex is correlated with cognitive decline in Alzheimer disease","volume":"29","author":"Kashani","year":"2008","journal-title":"Neurobiology of Aging"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib74","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0306-4522(97)00065-1","article-title":"4-Hydroxynonenal, an aldehydic product of membrane lipid peroxidation, impairs glutamate transport and mitochondrial function in synaptosomes","volume":"80","author":"Keller","year":"1997","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib75","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1073\/pnas.0510237103","article-title":"Serotonin 1A receptors in the living brain of Alzheimer's disease patients","volume":"103","author":"Kepe","year":"2006","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib76","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.neuropharm.2004.03.012","article-title":"5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation \u2013 an effect sensitive to NMDA receptor antagonism","volume":"47","author":"King","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib77","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/j.1471-4159.2006.03935.x","article-title":"Down-regulation of vesicular glutamate transporters precedes cell loss and pathology in Alzheimer's disease","volume":"98","author":"Kirvell","year":"2006","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib78","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1532-5415.1973.tb01661.x","article-title":"Comparison of thioridazine and diazepam in the control of nonpsychotic symptoms associated with senility: double-blind study","volume":"21","author":"Kirven","year":"1973","journal-title":"Journal of the American Geriatric Society"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib79","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1517\/13543784.9.10.2259","article-title":"Muscarinic M1 agonists in the treatment of Alzheimer's disease","volume":"9","author":"Korczyn","year":"2000","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib80","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/syn.10288","article-title":"5-HT6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex","volume":"51","author":"Lacroix","year":"2004","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib81","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1212\/WNL.57.5.805","article-title":"Psychosis of Alzheimer's disease is associated with elevated muscarinic M2 binding in the cortex","volume":"57","author":"Lai","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib82","series-title":"Neurobiology of Alzheimer's Disease","first-page":"245","article-title":"Alzheimer's disease as a neurotransmitter disease","author":"Lai","year":"2007"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib83","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00213-004-2077-2","article-title":"Loss of serotonin 5-HT2A receptors in the postmortem temporal cortex correlates with rate of cognitive decline in Alzheimer's disease","volume":"179","author":"Lai","year":"2005","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib84","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0006-8993(03)02554-X","article-title":"Reduced serotonin 5-HT1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer disease","volume":"974","author":"Lai","year":"2003","journal-title":"Brain Research"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib85","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/070674370404900705","article-title":"GABAergic function in Alzheimer's disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia","volume":"49","author":"Lanctot","year":"2004","journal-title":"Canadian Journal of Psychiatry"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib86","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00401-004-0820-8","article-title":"Aberrant expression of metabotropic glutamate receptor 2 in the vulnerable neurons of Alzheimer's disease","volume":"107","author":"Lee","year":"2004","journal-title":"Acta Neuropathologica (Berlin)"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib87","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/neu.10151","article-title":"Nicotinic receptor subtypes and cognitive function","volume":"53","author":"Levin","year":"2002","journal-title":"Journal of Neurobiology"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib88","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00213-005-0164-7","article-title":"Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization","volume":"184","author":"Levin","year":"2006","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib89","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.neuron.2009.05.012","article-title":"Soluble oligomers of amyloid \u03b2 protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake","volume":"62","author":"Li","year":"2009","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib90","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/brain\/111.4.785","article-title":"\u03b3-aminobutyric acid concentration in brain tissue at two stages of Alzheimer's disease","volume":"111","author":"Lowe","year":"1988","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib91","doi-asserted-by":"crossref","first-page":"15950","DOI":"10.1073\/pnas.0900903106","article-title":"Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation","volume":"106","author":"Ma","year":"2009","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib92","doi-asserted-by":"crossref","unstructured":"Marcos, B., Cabero, M., Solas, M., Aisa, B., Ramirez, M.J., 2009 Sep 9. Signalling pathways associated with 5-HT6 receptors: relevance for cognitive effects. International Journal of Neuropsychopharmacology, 1\u201310.","DOI":"10.1017\/S146114570999054X"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib93","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3233\/JAD-2008-14104","article-title":"Involvement of an altered 5-HT6 receptor function in behavioral symptoms of Alzheimer's disease","volume":"14","author":"Marcos","year":"2008","journal-title":"Journal of Alzheimers Disease"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib94","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/j.1460-9568.2006.05003.x","article-title":"Lack of localization of 5-HT6 receptors on cholinergic neurons: implication of multiple neurotransmitter systems in 5-HT6 receptor-mediated acetylcholine release","volume":"24","author":"Marcos","year":"2006","journal-title":"European Journal of Neuroscience"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib95","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1126\/science.3992249","article-title":"Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation","volume":"228","author":"Mash","year":"1985","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib96","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0006-3223(01)01235-5","article-title":"Noradrenergic changes, aggressive behavior, and cognition in patients with dementia","volume":"51","author":"Matthews","year":"2002","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib97","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1212\/WNL.46.1.130","article-title":"The spectrum of behavioral changes in Alzheimer's disease","volume":"46","author":"Mega","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib98","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1001\/archneur.56.11.1388","article-title":"The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease","volume":"56","author":"Mega","year":"1999","journal-title":"Archives of Neurology"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib99","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/ana.20100","article-title":"Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum","volume":"55","author":"Mesulam","year":"2004","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib100","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1212\/WNL.55.10.1460","article-title":"Cholinergic deficits contribute to behavioral disturbance in patients with dementia","volume":"55","author":"Minger","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib101","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2165\/00002512-200320140-00003","article-title":"Gabapentin for the treatment of behavioural alterations in dementia: preliminary 15-month investigation","volume":"20","author":"Moretti","year":"2003","journal-title":"Drugs and Aging"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib102","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1126\/science.278.5337.412","article-title":"Life and death of neurons in the aging brain","volume":"278","author":"Morrison","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib103","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1212\/WNL.38.4.606","article-title":"No response to high-dose muscarinic agonist therapy in Alzheimer's disease","volume":"38","author":"Mouradian","year":"1988","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib104","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/(SICI)1096-9861(19980105)390:1<112::AID-CNE10>3.0.CO;2-Z","article-title":"Localization of the m2 muscarinic acetylcholine receptor protein and mRNA in cortical neurons of the normal and cholinergically deafferented rhesus monkey","volume":"390","author":"Mrzljak","year":"1998","journal-title":"Journal of Comparative Neurology"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib105","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1212\/WNL.59.6.867","article-title":"Volumetric MRI predicts rate of cognitive decline related to AD and cerebrovascular disease","volume":"59","author":"Mungas","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0014-2999(97)83019-1","article-title":"Infusion of d-cycloserine into temporal-hippocampal areas and restoration of mnemonic function in rats with disrupted glutamatergic temporal systems","volume":"328","author":"Myhrer","year":"1997","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib107","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/BF00687139","article-title":"Regional weight loss of the cerebral cortex and some subcortical nuclei in senile dementia of the Alzheimer type","volume":"75","author":"Najlerahim","year":"1988","journal-title":"Acta Neuropathologica (Berlin)"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib108","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1042\/bj2510305","article-title":"Biochemical measurements in Alzheimer's disease reveal a necessity for improved neuroimaging techniques to study metabolism","volume":"251","author":"Najlerahim","year":"1988","journal-title":"Biochemical Journal"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib109","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/BF00711237","article-title":"Monoamine neurotransmitters and their metabolites in brain regions in Alzheimer's disease: a postmortem study","volume":"12","author":"Nazarali","year":"1992","journal-title":"Cellular and Molecular Neurobiology"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib110","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0006-3223(00)01125-2","article-title":"Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications","volume":"49","author":"Nordberg","year":"2001","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib111","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1192\/bjp.157.6.894","article-title":"The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study","volume":"157","author":"Nyth","year":"1990","journal-title":"British Journal of Psychiatry"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib112","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1177\/002383099200500108","article-title":"Incontinence and troublesome behaviors predict institutionalization in dementia","volume":"5","author":"O'Donnell","year":"1992","journal-title":"Journal of Geriatric Psychiatry and Neurology"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib113","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/BF03164869","article-title":"Preserved benzodiazepine receptors in Alzheimer's disease measured with C-11 flumazenil PET and I-123 iomazenil SPECT in comparison with CBF","volume":"13","author":"Ohyama","year":"1999","journal-title":"Annals of Nuclear Medicine"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib114","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/BF01245229","article-title":"Monoamine neurons in aging and Alzheimer's disease","volume":"91","author":"Palmer","year":"1993","journal-title":"Journal of Neural Transmission General Section"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib115","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1471-4159.1987.tb13120.x","article-title":"Presynaptic serotonergic dysfunction in patients with Alzheimer's disease","volume":"48","author":"Palmer","year":"1987","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib116","series-title":"Brain 5-HT1A Receptors","first-page":"286","article-title":"[3H]8-OH-DPAT binding in Alzheimer's disease: an index of pyramidal cell loss?","author":"Palmer","year":"1987"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib117","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2174\/156720510790274464","article-title":"Nicotinic Acetylcholine Receptor Interaction with \u03b2-Amyloid: Molecular, Cellular, and Physiological Consequences","volume":"7","author":"Parri","year":"2010","journal-title":"Current Alzheimer Research"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib118","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.neuropharm.2007.07.013","article-title":"Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system\u2014too little activation is bad, too much is even worse","volume":"53","author":"Parsons","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib119","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1136\/bmj.2.6150.1457","article-title":"Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia","volume":"2","author":"Perry","year":"1978","journal-title":"British Medical Journal"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib120","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1471-4159.1988.tb02983.x","article-title":"Evidence of glutamatergic denervation and possible abnormal metabolism in Alzheimer's disease","volume":"50","author":"Procter","year":"1988","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib121","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/j.1471-4159.1989.tb11760.x","article-title":"Reduced glycine stimulation of [3H]MK-801 binding in Alzheimer's disease","volume":"53","author":"Procter","year":"1989","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib122","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/sj.clpt.6100232","article-title":"A positron emission tomography study to assess binding of lecozotan, a novel 5-hydroxytryptamine-1A silent antagonist, to brain 5-HT1A receptors in healthy young and elderly subjects, and in patients with Alzheimer's disease","volume":"83","author":"Raje","year":"2008","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib123","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1176\/ajp.146.1.45","article-title":"Double-blind trial of imipramine in Alzheimer's disease patients with and without depression","volume":"146","author":"Reifler","year":"1989","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib124","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa013128","article-title":"Memantine in moderate-to-severe Alzheimer's disease","volume":"348","author":"Reisberg","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib125","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1021\/jm021085c","article-title":"Influence of the 5-HT6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl) phenylamine, a potent and selective 5-HT6 receptor antagonist","volume":"46","author":"Riemer","year":"2003","journal-title":"Journal of Medical Chemistry"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib126","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0006-8993(02)02360-0","article-title":"The distribution of 5-HT6 receptors in rat brain: an autoradiographic binding study using the radiolabelled 5-HT6 receptor antagonist [125I]SB-258585","volume":"934","author":"Roberts","year":"2002","journal-title":"Brain Research"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib127","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/bmj.288.6422.961","article-title":"Neurochemical characteristics of early and late onset types of Alzheimer's disease","volume":"288","author":"Rossor","year":"1984","journal-title":"British Medical Journal"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib128","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/archneur.63.12.1771","article-title":"Pathologic and nicotinic receptor binding differences between mild cognitive impairment, Alzheimer disease, and normal aging","volume":"63","author":"Sabbagh","year":"2006","journal-title":"Archives of Neurology"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib129","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.pscychresns.2009.03.007","article-title":"Regional distribution and behavioral correlates of 5-HT2A receptors in Alzheimer's disease with [18F]deuteroaltanserin and PET","volume":"173","author":"Santhosh","year":"2009","journal-title":"Psychiatry Research"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib130","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2174\/1381612023396483","article-title":"The potential utility of 5-HT1A receptor antagonists in the treatment of cognitive dysfunction associated with Alzheimer s disease","volume":"8","author":"Schechter","year":"2002","journal-title":"Current Pharmaceutical Design"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib131","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa061240","article-title":"Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease","volume":"355","author":"Schneider","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib132","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.euroneuro.2006.06.009","article-title":"Effects of the novel 5-HT6 receptor antagonist RO4368554 in rat models for cognition and sensorimotor gating","volume":"17","author":"Schreiber","year":"2007","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib133","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1212\/WNL.46.2.420","article-title":"d-Cycloserine enhances implicit memory in Alzheimer patients","volume":"46","author":"Schwartz","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib134","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/0306-4522(94)90491-X","article-title":"Human striatum: chemoarchitecture of the caudate nucleus, putamen and ventral striatum in health and Alzheimer's disease","volume":"60","author":"Selden","year":"1994","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib135","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1177\/106002809703100309","article-title":"Zolpidem for dementia-related insomnia and nighttime wandering","volume":"31","author":"Shelton","year":"1997","journal-title":"The Annals of Pharmacotherapy"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib136","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/j.1471-4159.1986.tb00753.x","article-title":"Biochemical characterization of \u03b1-adrenergic receptors in human brain and changes in Alzheimer-type dementia","volume":"47","author":"Shimohama","year":"1986","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib137","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/nn1503","article-title":"Regulation of NMDA receptor trafficking by amyloid-\u03b2","volume":"8","author":"Snyder","year":"2005","journal-title":"Nature Neuroscience"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib138","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1176\/ajp.147.8.1049","article-title":"Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease","volume":"147","author":"Steele","year":"1990","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib139","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1176\/appi.ajp.2008.07111779","article-title":"Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial","volume":"165","author":"Sultzer","year":"2008","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib140","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1523\/JNEUROSCI.4265-05.2006","article-title":"Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with Lewy bodies","volume":"26","author":"Szot","year":"2006","journal-title":"Journal of Neuroscience"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib141","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0033-3182(97)71461-0","article-title":"A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease","volume":"38","author":"Taragano","year":"1997","journal-title":"Psychosomatics"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib142","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/ana.410300410","article-title":"Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment","volume":"30","author":"Terry","year":"1991","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib143","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1177\/070674370705200407","article-title":"Efficacy and safety of antidepressants for treatment of depression in Alzheimer's disease: a meta-analysis","volume":"52","author":"Thompson","year":"2007","journal-title":"Canadian Journal of Psychiatry"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib144","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jns.2009.08.066","article-title":"A serotoninergic basis for hyperphagic eating changes in Alzheimer's disease","volume":"288","author":"Tsang","year":"2010","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib145","first-page":"1297","article-title":"Serotonin transporters are preserved in the neocortex of anxious Alzheimer's disease patients","volume":"14","author":"Tsang","year":"2003","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib146","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.neurobiolaging.2005.07.010","article-title":"Impaired coupling of muscarinic M1 receptors to G-proteins in the neocortex is associated with severity of dementia in Alzheimer's disease","volume":"27","author":"Tsang","year":"2006","journal-title":"Neurobiology of Aging"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib147","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.neurobiolaging.2006.06.001","article-title":"Disrupted muscarinic M1 receptor signaling correlates with loss of protein kinase C activity and glutamatergic deficit in Alzheimer's disease","volume":"28","author":"Tsang","year":"2007","journal-title":"Neurobiology of Aging"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib148","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.nurt.2008.05.008","article-title":"5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease","volume":"5","author":"Upton","year":"2008","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib149","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0197-4580(99)00035-4","article-title":"Phenotypic down-regulation of glutamate receptor subunit GluR1 in Alzheimer's disease","volume":"20","author":"Wakabayashi","year":"1999","journal-title":"Neurobiology of Aging"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib150","doi-asserted-by":"crossref","first-page":"342","DOI":"10.2174\/156720508784533286","article-title":"Functional consequences of locus coeruleus degeneration in Alzheimer's disease","volume":"5","author":"Weinshenker","year":"2008","journal-title":"Current Alzheimer Research"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib151","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.neuropharm.2007.01.007","article-title":"Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression","volume":"52","author":"Wesolowska","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib152","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s00702-003-0012-z","article-title":"Synaptic vesicle transport and synaptic membrane transporter sites in excitatory amino acid nerve terminals in Alzheimer disease","volume":"110","author":"Westphalen","year":"2003","journal-title":"Journal of Neural Transmission"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib153","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1126\/science.7058341","article-title":"Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain","volume":"215","author":"Whitehouse","year":"1982","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib154","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0022-510X(82)90045-4","article-title":"Alzheimer's disease. Correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities","volume":"57","author":"Wilcock","year":"1982","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib155","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2174\/1568007043482561","article-title":"5-HT6 receptors","volume":"3","author":"Woolley","year":"2004","journal-title":"Current Drug Targets \u2013CNS and Neurological Disorders"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib156","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s00213-003-1552-5","article-title":"Reversal of a cholinergic-induced deficit in a rodent model of recognition memory by the selective 5-HT6 receptor antagonist, Ro 04-6790","volume":"170","author":"Woolley","year":"2003","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib157","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/archneur.1990.00530020117023","article-title":"Neurochemical correlates of major depression in primary dementia","volume":"47","author":"Zubenko","year":"1990","journal-title":"Archives of Neurology"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib158","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/archneur.1991.00530180075020","article-title":"Neuropathologic and neurochemical correlates of psychosis in primary dementia","volume":"48","author":"Zubenko","year":"1991","journal-title":"Archives of Neurology"},{"key":"10.1016\/j.neuropharm.2010.02.010_bib159","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/ana.410240210","article-title":"The neuropathology of aminergic nuclei in Alzheimer's disease","volume":"24","author":"Zweig","year":"1988","journal-title":"Annals of Neurology"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390810000432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390810000432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T08:39:32Z","timestamp":1739867972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390810000432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":159,"journal-issue":{"issue":"4-5","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0028390810000432"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2010.02.010","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}